Subscribe
eldora-ellison
28 October 2020BiotechnologySarah Morgan

LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101

Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler  Goldstein & Fox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN Connect: Monetising your IP portfolio
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Genetics
Webinar: Plenty to fight for in CRISPR IP battle
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
LSPN Connect: Monetising your IP portfolio
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Genetics
Webinar: Plenty to fight for in CRISPR IP battle
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

More on this story

Big Pharma
LSPN Connect: Monetising your IP portfolio
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Genetics
Webinar: Plenty to fight for in CRISPR IP battle
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB